



## **ISPOR Russia St. Petersburg Chapter**

### **Annual Report 2023**

To: Board of Directors

International Society for Pharmacoeconomics and  
Outcomes Research

505 Lawrence Square Boulevard

South Lawrenceville, TO 08648 USA

### **PREPARED BY**

Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Faculty of Medicine, St. Petersburg State University; chief editor of the journal “Real-World Data and Evidence”

Yulia E. Balykina, PhD, associate professor, St Petersburg State University, faculty of Applied Mathematics and Control Processes.

### **President of ISPOR Russia St. Petersburg Regional Chapter**

Alexey S. Kolbin, MD, PhD, Doctor of Science, Professor, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Faculty of Medicine, St. Petersburg State University, St. Petersburg, Russia; chief editor of the journal “Real-World Data and Evidence”

### **President-Elect**

Sergey K. Zyryanov, MD, PhD, Professor, Head of the Department of Clinical Pharmacology of the RUDN University, Moscow, Russia; chief editor of the “Good clinical practice” journal

### **Executive Director**

Dmitry Yu. Belousov, Science Editor of the “Good clinical practice”, “Real-World Data & Evidence”; General Director of Center for Pharmacoeconomic Research, Moscow, Russia

### **Secretary**

Alexey A. Kurylev, MD, Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.

## Activities of the Chapter in 2023:

### I. Publications in the Field of Pharmacoeconomics and Health Technology Assessment

№	Title	Journal	Authors
1	Efficiency of Levilimab in patients with moderate and severe COVID-19	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(1):36–47. DOI: <a href="https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.164">https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.164</a>	Gomon Yu.M., Strizheletsky V.V., Ivanov I.G., Balykina Yu.E., Ermolyev M.V., Kolbin A.S., Livshits M.V., Usmanova T.A., Fakhruddinova A.M., Konstantinova Yu.S., Gubanov A.P.
2	The use of janus kinase inhibitors anti-interleukin therapy in the Russian Federation with COVID-19: pharmacoepidemiological study	HIV Infection and Immunosuppressive Disorders. 2023;15(1):41-49. DOI: <a href="https://doi.org/10.22328/2077-9828-2023-15-1-41-49">https://doi.org/10.22328/2077-9828-2023-15-1-41-49</a>	Gomon Yu.M., Strizheletsky V.V., Ivanov I.G., Kolbin A.S., Kalyapin A.A., Fakhruddinova A.M., Usmanova T.A.
3	Clinical and economic analysis of bariatric interventions in the treatment of obesity in the Russian Federation	Endoscopic Surgery. 2023;29(3):5-14. DOI: <a href="https://doi.org/10.17116/endoskop2023290315">https://doi.org/10.17116/endoskop2023290315</a>	Strizheletsky V.V., Gomon Yu.M., Spichakova E.A., Kolbin A.S., Makarov S.A., Lomia A.B., Sultanova F.M., Budanov D.S.
4	A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy	Antibiotics and Chemotherapy. 2023;68(3-4):52-65. DOI: <a href="https://doi.org/10.37489/0235-2990-2023-68-3-4-52-65">https://doi.org/10.37489/0235-2990-2023-68-3-4-52-65</a>	Gomon Yu.M., Kolbin A.S., Fakhruddinova A.M., Usmanova T.A., Sultanova F.M., Balykina Yu.E.
5	Socio-economic burden of atrial fibrillation in the Russian Federation: dynamics over 12 years	Good Clinical Practice. 2023;(2):53-58. DOI: <a href="https://doi.org/10.37489/2588-0519-2023-2-53-58">https://doi.org/10.37489/2588-0519-2023-2-53-58</a>	Kasimova A.P., Tufanova O.S., Kolbin A.S.
6	Dynamics of Reserve Antimicrobial Drug Consumption in Russian	Antibiotics and Chemotherapy. 2023;68(5-6):62-68. DOI: <a href="https://doi.org/10.37489/0235-2990-2023-68-5-6-62-68">https://doi.org/10.37489/0235-2990-2023-68-5-6-62-68</a>	Gomon Y.M., Kolbin A.A., Budanov D.S.

	Hospitals: Impact of the COVID-19 Pandemic	<a href="https://doi.org/10.37489/0235-2990-2023-68-5-6-62-68">https://doi.org/10.37489/0235-2990-2023-68-5-6-62-68</a>	
<b>7</b>	Economic efficiency of long-term oxygen therapy in patients with chronic lung diseases and severe chronic hypoxemia	Russian Medical Inquiry. 2023;7(8):475–481 DOI: 10.32364/2587-6821-2023-7-8-1	Gomon Yu. M. Titova O. N., Kolbin A. S., Kuzubova N. A., Balykina Yu. E.
<b>8</b>	Medical technologies assessment in COVID-19	HIV Infection and Immunosuppressive Disorders. 2023;15(3):105-115. DOI: <a href="https://doi.org/10.22328/2077-9828-2023-15-3-105-115">https://doi.org/10.22328/2077-9828-2023-15-3-105-115</a>	Kolbin A.S., Gomon Yu.M.
<b>9</b>	Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(3):412-421. DOI: <a href="https://doi.org/10.17749/2070-4909/farmakoeconomika.2023.210">https://doi.org/10.17749/2070-4909/farmakoeconomika.2023.210</a>	Kolbin A.S., Gomon Yu.M., Proskurin M.A., Balykina Yu.E.
<b>10</b>	Role of RWD / RWE in health technology assessment	Real-World Data & Evidence. 2023;3(1):1-8. DOI: <a href="https://doi.org/10.37489/2782-3784-myrd-26">https://doi.org/10.37489/2782-3784-myrd-26</a>	Borovskaya V.G., Kurylev A.A.
<b>11</b>	Assessing the risks of abuse of opioids in real-world data	Real-World Data & Evidence. 2023;3(1):30-40. DOI: <a href="https://doi.org/10.37489/2782-3784-myrd-29">https://doi.org/10.37489/2782-3784-myrd-29</a>	Pchelintsev M.V.
<b>12</b>	Overview of FDA guidelines for patient engagement in medical product development and regulatory decision making	Real-World Data & Evidence. 2023;3(2):1-9. DOI: <a href="https://doi.org/10.37489/2782-3784-myrd-31">https://doi.org/10.37489/2782-3784-myrd-31</a>	Borovskaya V.G., Kasimova A.R.
<b>13</b>	Drug utilization research at the individual level as the main concept of pharmacoepidemiology	Real-World Data & Evidence. 2023;3(2):21-30. DOI: <a href="https://doi.org/10.37489/2782-3784-myrd-33">https://doi.org/10.37489/2782-3784-myrd-33</a>	Mukhina S.M., Baranova M.I., Gomon Yu.M.
<b>14</b>	Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review	Real-World Data & Evidence. 2023;3(2):42-55. DOI: <a href="https://doi.org/10.37489/2782-3784-myrd-35">https://doi.org/10.37489/2782-3784-myrd-35</a>	Motrinchuk A.Sh., Loginovskaya O.A., Kolbatov V.P.

<b>15</b>	Piperacillin-tazobactam: prospects for use in real-world practice	Real-World Data & Evidence. 2023;3(3):1-7. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-36">https://doi.org/10.37489/2782-3784-myrwd-36</a>	Gomon Yu.M.
<b>16</b>	Analyzing FDA's approaches to using electronic health record and medical claims data to support regulatory decision making	Real-World Data & Evidence. 2023;3(3):28-35. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-39">https://doi.org/10.37489/2782-3784-myrwd-39</a>	Radaeva K.S., Pchelintsev M.V.
<b>17</b>	Resolution based on the results of the IV annual scientific-practical conference "Real clinical practice. Modernity and the future"	Real-World Data & Evidence. 2023;3(4):1-8. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-41">https://doi.org/10.37489/2782-3784-myrwd-41</a>	Kolbin A.S. on behalf of the Working Group on RWD/RWE in the Russian Federation
<b>18</b>	Review of data sources used in real-world traumatology and orthopedic	Real-World Data & Evidence. 2023;3(4):9-14. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-42">https://doi.org/10.37489/2782-3784-myrwd-42</a>	Zolotukhina I.U., Kasimova A.R.
<b>19</b>	Prospects for the use of allosteric drugs in real-world clinical practice	Real-World Data & Evidence. 2023;3(4):15-21. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-43">https://doi.org/10.37489/2782-3784-myrwd-43</a>	Svechkareva I.R., Kolbin A.S.
<b>20</b>	Proposed changes ICER 2023 value assessment framework	Real-World Data & Evidence. 2023;3(4):22-28. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-44">https://doi.org/10.37489/2782-3784-myrwd-44</a>	Svechkareva I.R., Kurylev A.A.
<b>21</b>	Considerations for the design and conduct of externally controlled trials for drug and biological products	Real-World Data & Evidence. 2023;3(4):29-40. DOI: <a href="https://doi.org/10.37489/2782-3784-myrwd-45">https://doi.org/10.37489/2782-3784-myrwd-45</a>	Motrinchuk A.S., Belousov D.Yu.
<b>22</b>	Adjuvant hormone therapy in early-stage estrogen-positive breast cancer: a systematic review and network meta-analysis	Patient-Oriented Medicine and Pharmacy. 2023;1(2):75-84. DOI: <a href="https://doi.org/10.37489/2949-1924-0017">https://doi.org/10.37489/2949-1924-0017</a>	Belousov D.Yu., Cheberda A.E.
<b>23</b>	Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure	Kardiologiia. 2023;63(5):19-26. DOI: <a href="https://doi.org/10.18087/cardi.o.2023.5.n2378">https://doi.org/10.18087/cardi.o.2023.5.n2378</a>	Rudakova A.V., Brico N.I., Lobzin Yu.V., Namazova-Baranova L.S., Avdeev S.N., Kostinov M.P.,

			Korshunov V.A., Fomin I.V.
24	A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation	Epidemiology and Vaccinal Prevention. 2023;22(4):106-139. DOI: <a href="https://doi.org/10.31631/2073-3046-2023-22-4-106-139">https://doi.org/10.31631/2073-3046-2023-22-4-106-139</a>	Briko N.I., Korshunov V.A., Lobzin J.V., Namazova-Baranova L.S., Rudakova L.V., Simonova E.G.
25	Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis	Good Clinical Practice. 2023;(2):70-84. DOI: <a href="https://doi.org/10.37489/2588-0519-2023-2-70-84">https://doi.org/10.37489/2588-0519-2023-2-70-84</a>	Zyryanov S.K., Dyakov I.N., Ilina N.I.
26	Updated pharmacoeconomic analysis of atezolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy	FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(3):422-430. DOI: <a href="https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.211">https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.211</a>	Zyryanov S.K., Dyakov I.N.
27	Organizing the large multiple-center clinical trials based on modern digital approaches during the pandemic of a novel coronavirus infection in Moscow	Medical Technologies. Assessment and Choice. 2023;(3):82-92. DOI: <a href="https://doi.org/10.17116/medtech20234503182">https://doi.org/10.17116/medtech20234503182</a>	Kucheryavykh E.S., Karpova Yu.N., Panarina Ya.S., Starshinin A.V., Tsareva E.A., Bezemyanny A.S., Komarov A.G., Shtinova I.A., Shpakova O.G., Slutsky E.A., Pakhuridze M.D., Rusantsova N.A., Zyryanov S.K., Brazhnikov A.Yu.
28	Urban ecosystem for clinical research	Moscow medicine. 2023;6(58):14-19.	Zyryanov S.K.
29	Adherence to treatment. Russian national guidance. A short edition for medical practitioners	Therapy. 2023;9(S1 (63)):1-108.	Nikolaev N.A., Martynov A.I., Skirdenko Yu.P.,

			Avdeev V.N., Zyryanov S.K., Konradi A.O., Lazebnik L.B., et al.

## II. Oral Presentations in the Field of Pharmacoeconomics and Health Technology Assessment at Russian and International Conferences

№	Conference Title	Organizers	Report Title	Dates	Venue
1	XIV International Eurasian Pharmaceutical Forum	Ministry of Health of the Republic of Kazakhstan	RWD/RWE as a decision-making tool in healthcare	01.03.2023	Alma-Ata
2	XV Annual All-Russian Congress on Infectious Diseases (congress with international participation)	Ministry of Health of the Russian Federation (MH RF)	Assessment of the use of tocilizumab for COVID-19 treatment	27.03.2023	Moscow
3	Expert Council on the topic “Assessment of clinical and economic indicators of the effectiveness of drugs and their impact on inclusion in government funding programs.”	Association of Clinical Pharmacologists	Real practice of clinical and economic studies of drugs in the formation of restrictive lists. Open data for expert analysis	30.03.2023	Volgograd
4	VIII Scientific Conference “Strategy for Controlling Antibiotic Resistance in Hospitals: Problems and Prospects”	MH RF	The burden of antibiotic resistance - what do we have to lose?	04.04.2023	Moscow
5	II All-Russian scientific conference with international participation “Pharmaceutical science: challenges and solutions in the 21st century”	IPHEB	Assessment of medical technologies when making decisions on the advisability of reimbursement of drug costs	11.04.2023	St. Petersburg

	within the framework of the business forum in the field of pharmaceuticals and biotechnology IPHEB RUSSIA				
6	Real-world data and real world evidence (RWD/RWE) in oncology and hematology	Russian Medical Academy of Continuous Professional Education (RMACPE); MH RF	Can RWE in modern realities affect clinical practice and, if so, how?	18.04.2023	Moscow
7	IX Interregional scientific symposium with international participation “Pharmacoeconomics of viral infections”	Health Committee of the St. Petersburg Government; Russian Academy of Sciences (RAN)	Health technology assessment for COVID-19	20.04.2023	St. Petersburg
8	XXII Interregional Scientific Conference “Medicine and Human Health”	MH RF	The concept of real world data: the current state of the problem	21.04.2023	Astrakhan
9	Current issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices	MH RF	Paradigm of real world data: from data analysis to decision making	24.04.2023	St. Petersburg
10	XXX Russian Pharmaceutical Forum named after N.A. Semashko	MH RF; RAS	RWD/RWE Data Capabilities and Experience	17.05.2023	St. Petersburg
11	All-Russian meeting “Current issues of clinical pharmacology and drug supply”	Association of Clinical Pharmacologists of the Russian Federation	The role of real-world data in health technology assessment	18.05.2023	Moscow

12	XXV IACMAC Congress on Antimicrobial Therapy and Clinical Microbiology	The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC); MH RF; RAS	Evidence-based medicine: the role of real-world data	25.05.2023	Moscow
13	III All-Russian Scientific Conference with international participation “Personalized Psychiatry and Neurology” and III International School of Young Scientists on Personalized Psychiatry and Neurology	MH RF; RAS	The concept of RWE/RWD in the EAEU and in the world	26.05.2023	St. Petersburg
14	IX Oncology Forum «White Nights 2023», Current trends in the development of pharmacoconomics	MH RF; RAS	The current state of the RWE/RWD paradigm	08.07.2023	St. Petersburg
15	IV international conference “Real clinical practice. Modernity and the future”	Association of Specialists in HTA	RWE/RWD. Modernity and future	28.09.2023	Moscow
16	Congress of Therapists of the Northwestern Federal District. “Main directions of clinical pharmacology in post-COVID times” Symposium	Health Committee of the St. Petersburg Government	From the concept of real clinical practice to recommendations: international experience	15.12.2023	St. Petersburg
17	IX St. Petersburg International Oncology Forum «White Nights 2023»	MH RF; RAS	Vaccine prevention of HPV-associated diseases: pharmaco-economic aspects	08.07.2023	St. Petersburg



18	X Interregional scientific symposium with international participation “Pharmacoeconomics of viral infections”	North-West District Center for the Prevention and Control of AIDS of the St. Petersburg Research Institute; Baltic Research Center in the Field of Medicine	Pharmacoeconomic aspects of vaccine prevention of viral infections (HPV, rotavirus, chickenpox)	20.04.2023	St. Petersburg
19	II All-Russian Forum of Heads of Hematology Departments and Chief Hematologists of the Subjects of the Russian Federation	NPO Scientific medical community; Federal State Institution “National Research Institute of Public Health named after N.A. Semashko”, Moscow	Clinical and economic indicators of the effectiveness of drugs and their impact on inclusion in government funding programs	3-4.03.2023	Moscow
20	V Scientific Conference with International Participation “Modern Challenges in Infection Therapy”	RUDN University, City Clinical Hospital No. 24 of the Moscow Healthcare Department	Clinical and economic indicators of the effectiveness of drugs and their impact on inclusion in government funding programs	22.03.2023	Moscow
21	Russian congress “Safety of pharmacotherapy 360: NOLI NOCERE”	RMACPE; Moscow	Prospects for improving the high-cost technology program	16-19.05.2023	Moscow
22	Preferential drug provision for patients: problems and development prospects	NPO Scientific medical community; Federal State Institution “National Research Institute of Public Health named after N.A. Semashko”, Moscow	Modern achievements and prospects for improving drug provision for patients with oncohematological diseases	23.05.2023	Moscow

23	Expert Council “Increasing the availability of drugs for the treatment of diabetes mellitus”	National Medical Research Center of Endocrinology of the Russian Ministry of Health	Pharmacoeconomic analysis for new classes of antidiabetic drugs. Issues of comprehensive assessment of a fixed combination of doses of drugs and the inclusion of combinations in vital and essential drug lists	14.06.2023	Moscow
24	III Forum of administrators of medical oncology organizations under the auspices of the Association of Oncologists of Russia	BIOCAD; Sochi	Pharmacoeconomic specificity of the 1st line therapy for patients with metastatic melanoma with a mutation in the BRAF gene	20- 22.10.2023	Sochi
25	International Congress “Rational pharmacotherapy”	Association of Clinical Pharmacologists of St. Petersburg	Possibilities of using real-world data in assessing the effectiveness of antitumor drug therapy	13.10.2023	St. Petersburg
26	IX Oncology Forum «White Nights 2023», Current trends in the development of pharmacoeconomics	MH RF; RAS	Experience in digitalization of medical prescriptions	08.07.2023	St. Petersburg
27	Clinical Research Dialogues	International exhibition and forum on pharmaceuticals and biotechnology	Processing RWE/RWD data in clinical trials	26.10.2023	St. Petersburg

### III. ISPOR Chapter Journal

1. Good Clinical Practice. [www.clinvest.ru](http://www.clinvest.ru)
2. Real-World Data & Evidence [www.myrwd.ru/jour](http://www.myrwd.ru/jour)

#### IV. Branch Interaction with Authorities

1. Participation in the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health.
2. Participation in the Committee of the Ministry of Health of the Russian Federation on the formation of restrictive drug lists of the Ministry of Health of the Russian Federation.
3. Participation in the Working group on the formation general approaches to drug regulation within the framework of the Eurasian Economic Union.
4. Development of the Concept for the Development of Approaches to the Collection, Analysis and Use of Real World Data in the Member States of the Eurasian Economic Union (RWD / RWE).
5. Participation in the work of the Committee on drug provision for benefit-entitled categories of citizens of St. Petersburg.
6. Participation in the work of two expert organizations on the Ministry of Health Rules for the formation of drug lists.

#### V. Chapter Interaction with Professional Organizations

1. Participation in the work of the All-Russian Association of Clinical Pharmacologists
2. Participation in the work of the Educational and Methodical Committee on Clinical Pharmacology under the Russian Federation Ministry of Health

#### VI. Chapter Websites

- <http://www.labclinpharm.ru>
- <http://www.healtheconomics.ru>
- YouTube channel:  
<https://www.youtube.com/playlist?list=PLrajN8RdElyoRDKBcWVdhyawjsTJ8rUIQ>

#### VII. Educational Programs and Seminars

1. On the basis of the Pavlov First Saint Petersburg State Medical University, an educational cycle for doctors was organized within the framework of continuing medical education (the cycle information is posted on the Continuing Medical and Pharmaceutical Education Portal (<http://edu.rosminzdrav.ru/>): “Current Issues of Health Technology Assessment”, October 2023.
2. An elective course “Fundamentals of Pharmacoeconomics” for the 5<sup>th</sup> year students of the pharmaceutical faculty of the St. Petersburg State Chemical and Pharmaceutical University (SPCPA), and elective course “Pharmacoeconomics of innovative drugs” for students of the Master’s degree program for the “Biotechnology” specialty in SPCPA are organized annually.
3. On the basis of the Pavlov First St. Petersburg State Medical University, for the first time in Russia an educational cycle for doctors was organized and held: “Real clinical practice: real-world data and real-world evidence”.
4. Preparation and publication of a textbook: Real clinical practice studies. Updated 2023 recommendations. / under the general editorship of A. S. Kolbin - M.: OKI Publishing House, 2023. - 222 pp.: ill. ISBN 978-5-907715-17-2

## **VIII. Organizational Work**

1. Within the framework of the X All-Russian conference with international participation “Current issues of preclinical and clinical trials of drugs, biomedical cell products and clinical trials of medical devices”, the section “RWD / RWE” was organized and held on April 24, 2023.
2. Within the framework of the X All-Russian conference with international participation “Current issues of preclinical and clinical trials of drugs, biomedical cell products and clinical trials of medical devices”, the Pharmacovigilance section was organized and held on April 24, 2023.
3. X Interregional Scientific Symposium with international participation “Pharmacoeconomics of Viral Infections” was organized and held on April 20, 2023.
4. As part of the IX St. Petersburg International Oncology Forum “White Nights – 2023” The Symposium “Current trends in the development of pharmacoeconomics”, was organized and held on July 8, 2023.
5. IV Annual Scientific Conference with international participation “Real World Data in a Changing World. Challenges and Solutions” was organized and held on September 28, 2023.

## **X. Chapter Plans for the Future**

1. Development of recommendations “General approaches to obtaining, analyzing and using RWD in the life cycle of a medicinal product” within the framework of the Eurasian Economic Union.
2. Organization of the RWD / RWE and Pharmacovigilance Sections as part of the XI All-Russian Conference with international participation “Current issues of preclinical and clinical trials of drugs, biomedical cell products and clinical trials of medical devices” in April 2024.
3. Organization of the V Scientific conference with international participation “Real clinical practice” in September 2024.
4. Organization of the second educational cycle for doctors “Real clinical practice: real-world data and real-world evidence” on the base of the Pavlov First St. Petersburg State Medical University in October 2024.